GSK3B and early-onset autosomal dominant Alzheimer disease: GYY4137 exhibits neuroprotective effects in Alzheimer's disease models by promoting the sulfhydration of glycogen synthase kinase 3β (GSK3β), thereby inhibiting tau hyperphosphorylation, a critical step in neurofibrillary tangle formation.